Related Experiment Videos
Biological dosimetry for epithermal neutron beams.
S M White1, K D Held, M R Palmer
1Department of Nuclear Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Radiation Research
|May 16, 2001
Summary
This study evaluated the radiobiological effectiveness of epithermal neutron beams, finding cell survival increased with phantom depth due to neutron attenuation. These findings are relevant for boron neutron capture therapy clinical trials.
Area of Science:
- Radiobiology
- Medical Physics
- Radiation Oncology
Background:
- Epithermal neutron beams are utilized in boron neutron capture therapy (BNCT).
- Understanding the biological effectiveness of neutron and photon components is crucial for BNCT clinical trials.
- Healthy tissue toxicity is a key endpoint in Phase I/II BNCT trials.
Purpose of the Study:
- To determine the radiobiological effectiveness of an epithermal neutron beam using Chinese hamster ovary (CHO) cell survival.
- To assess how neutron beam components are moderated and attenuated at various depths in tissue.
- To establish relative biological effectiveness (RBE) values compared to X-ray irradiation.
Main Methods:
- Irradiation of CHO cells using the M67 epithermal neutron beam at Massachusetts Institute of Technology.
- Cell survival assays performed at seven depths (0.5-8.1 cm) in a water phantom simulating healthy tissue.
- Comparison of cell survival data with 250 kVp X-ray irradiations to calculate RBE values.
Main Results:
- Cell survival was significantly dependent on phantom depth.
- Lowest cell survival was observed at the shallowest depth (0.5 cm).
- Cell survival gradually increased with increasing depth, correlating with the exponential decrease in fast-neutron intensity.
Conclusions:
- The radiobiological effectiveness of the epithermal neutron beam, excluding boron, varies with depth due to beam attenuation.
- Findings provide essential data for optimizing dose delivery and predicting healthy tissue toxicity in BNCT.
- Results directly inform clinical BNCT Phase I/II trials by quantifying RBE and depth-dependent effects.